2893 A. Efficacy and Safety of Aztreonam-Avibactam for the Treatment of Serious Infections Due to Gram-Negative Bacteria, Including Metallo-β-Lactamase-Producing Pathogens: Phase 3 REVISIT Study
Yehuda Carmeli(Israel Ministry of Health), Joseph W. Chow(Pfizer (United States)), Rienk Pypstra(Pfizer (United States)), Minggui Wang(Fudan University), Francis F. Arhin(Pfizer (Canada)), Julián Torre Cisneros(Hospital Universitario Reina Sofía), Georgios Daikos(Laiko General Hospital of Athens), Joanne L. Leaney(Pfizer (United Kingdom)), O. V. Pyptіuk(Ivano-Frankivsk National Medical University), Firdevs Aksoy(Karadeniz Technical University), Mical Paul(Rabin Medical Center), Jose-Miguel Cisneros(Hospital Universitario Reina Sofía), Michele Wible, Yongjie Zhao(Tianjin People's Hospital), Lu Liang(Baotou Central Hospital), Rosa-María Jiménez Rodríguez(Instituto de Biomedicina de Sevilla), Halley Rogers(Pfizer (United States)), Ivan Titov(Ivano-Frankivsk National Medical University), Alison Luckey(Global Antibiotic Research & Development Partnership), George Singer(UCLA Medical Center), Gang Chen(The First Hospital of Kunming), Illia Gumenchuk(Kyiv City Clinical Oncology Center)
Cited by 25
Related Papers
Anidulafungin versus Fluconazole for Invasive Candidiasis
|New England Journal of Medicine|2007|896
Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study
|The Lancet Infectious Diseases|2017|521
Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis
|Cochrane Database of Systematic Reviews|2014|376